

Fuyuhiko Motoi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1245526/publications.pdf>

Version: 2024-02-01

79
papers

2,482
citations

186265
28
h-index

206112
48
g-index

82
all docs

82
docs citations

82
times ranked

3183
citing authors

#	ARTICLE	IF	CITATIONS
1	Development, validation, and comparison of a nomogram based on radiologic findings for predicting malignancy in intraductal papillary mucinous neoplasms of the pancreas: An international multicenter study. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2023, 30, 133-143.	2.6	7
2	Potential urinary function benefits of initial robotic surgery for rectal cancer in the introductory phase. <i>Journal of Robotic Surgery</i> , 2022, 16, 159-168.	1.8	4
3	A case of successful removal of a migrated fish bone in the bile duct after pancreaticoduodenectomy using overtube-assisted cholangioscopy. <i>Clinical Journal of Gastroenterology</i> , 2022, 15, 493.	0.8	1
4	Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study). <i>Trials</i> , 2022, 23, 119.	1.6	6
5	Levels of tumor markers <sc>CEA</sc>/<sc>CA</sc> 19â€“9 in serum and peritoneal lavage predict postoperative recurrence in patients with pancreatic cancer. <i>Annals of Gastroenterological Surgery</i> , 2022, 6, 862-872.	2.4	5
6	Staging laparoscopy is mandatory for the treatment of pancreatic cancer to avoid missing radiologically negative metastases. <i>Surgery Today</i> , 2021, 51, 686-694.	1.5	31
7	Overcoming acquired chemo-resistance to gemcitabine: implications from the perspective of multi-modal therapy including surgery for pancreatic cancer. , 2021, 4, 881-884.		0
8	A case of a smooth transition to subsequent percutaneous transjejunal biliary intervention for hepatolithiasis after biliary reconstruction by adding jejunostomy during an emergency operation for perforation due to balloon-assisted endoscopy. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 678-683.	0.8	0
9	Effectiveness of neoadjuvant chemotherapy for patients with resectable pancreatic cancer. <i>Suizo</i> , 2021, 36, 3-11.	0.1	0
10	Pathways for the development of multiple epithelial types of intraductal papillary mucinous neoplasm of the pancreas. <i>Journal of Gastroenterology</i> , 2021, 56, 581-592.	5.1	11
11	Prognostic value of an inflammation-based nutritional score for patients with initially unresectable pancreatic adenocarcinoma undergoing conversion surgery following chemo-/radiotherapy. <i>Surgery Today</i> , 2021, 51, 1682-1693.	1.5	4
12	Pancreatitis with local recurrence of renal cell carcinoma involving the main pancreatic duct. <i>Suizo</i> , 2021, 36, 135-141.	0.1	0
13	Development of a system combining comprehensive genotyping and organoid cultures for identifying and testing genotype-oriented personalised medicine for pancreatobiliary cancers. <i>European Journal of Cancer</i> , 2021, 148, 239-250.	2.8	10
14	Germline DNA damage repair gene mutations in pancreatic cancer patients with personal/family histories of pancreas/breast/ovarian/prostate cancer in a Japanese population. <i>Annals of Gastroenterological Surgery</i> , 2021, 5, 853-864.	2.4	5
15	Circulating tumor DNA as a predictive marker for occult metastases in pancreatic cancer patients with radiographically nonâ€“metastatic disease. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 648-658.	2.6	10
16	Silencing of LRRFIP1 enhances the sensitivity of gemcitabine in pancreatic cancer cells by activating JNK/c-Jun signaling. <i>Pancreatology</i> , 2021, 21, 771-778.	1.1	4
17	Transanal total mesorectal excision and transabdominal robotic surgery for rectal cancer: A retrospective study. <i>Annals of Medicine and Surgery</i> , 2021, 70, 102902.	1.1	4
18	Precise anatomical resection based on structures of nerve and fibrous tissue around the superior mesenteric artery for mesopancreas dissection in pancreaticoduodenectomy for pancreatic cancer. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, e6-e7.	2.6	0

#	ARTICLE	IF	CITATIONS
19	Laparoscopic Proctocolectomy With Transanal Total Mesorectal Excision for Ulcerative Colitis. <i>Cureus</i> , 2021, 13, e19720.	0.5	1
20	Prognostic value of FDG-PET radiomics with machine learning in pancreatic cancer. <i>Scientific Reports</i> , 2020, 10, 17024.	3.3	42
21	Stromal expression of hemopexin is associated with lymph-node metastasis in pancreatic ductal adenocarcinoma. <i>PLoS ONE</i> , 2020, 15, e0235904.	2.5	10
22	Risk prediction for malignant intraductal papillary mucinous neoplasm of the pancreas: logistic regression versus machine learning. <i>Scientific Reports</i> , 2020, 10, 20140.	3.3	11
23	GNAS mutation detection in circulating cell-free DNA is a specific predictor for intraductal papillary mucinous neoplasms of the pancreas, especially for intestinal subtype. <i>Scientific Reports</i> , 2020, 10, 17761.	3.3	19
24	Prognostic impact of intraoperative peritoneal cytology after neoadjuvant therapy for potentially resectable pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 1711-1717.	1.1	12
25	Epigenetic inactivation of IRX4 is responsible for acceleration of cell growth in human pancreatic cancer. <i>Cancer Science</i> , 2020, 111, 4594-4604.	3.9	6
26	Risk factors for pancreatic fistula grade C after pancreatoduodenectomy: A large prospective, multicenter Japan-Taiwan collaboration study. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2020, 27, 622-631.	2.6	23
27	Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol?. <i>Annals of Gastroenterological Surgery</i> , 2020, 4, 100-108.	2.4	35
28	Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 483-489.	1.3	44
29	Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy. <i>Surgery</i> , 2020, 167, 803-811.	1.9	32
30	Methylation-mediated silencing of the LIM homeobox 6 (LHX6) gene promotes cell proliferation in human pancreatic cancer. <i>Biochemical and Biophysical Research Communications</i> , 2020, 526, 626-632.	2.1	6
31	Mechanism of Bile Acid Reabsorption in the Biliopancreatic Limb After Duodenal-jejunal Bypass in Rats. <i>Obesity Surgery</i> , 2020, 30, 2528-2537.	2.1	11
32	Title is missing!. , 2020, 15, e0235904.		0
33	Title is missing!. , 2020, 15, e0235904.		0
34	Title is missing!. , 2020, 15, e0235904.		0
35	Title is missing!. , 2020, 15, e0235904.		0
36	Collagen gel droplet-embedded culture drug sensitivity test (CD-DST) predicts the effect of adjuvant chemotherapy on pancreatic cancer. <i>Surgery Today</i> , 2019, 49, 1035-1043.	1.5	5

#	ARTICLE	IF	CITATIONS
37	Decreased serum carbohydrate antigen 19â€“9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients. <i>BMC Cancer</i> , 2019, 19, 252.	2.6	57
38	Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis. <i>Surgery Today</i> , 2019, 49, 295-299.	1.5	41
39	Changes in Enterohepatic Circulation after Duodenalâ€“Jejunal Bypass and Reabsorption of Bile Acids in the Bilio-Pancreatic Limb. <i>Obesity Surgery</i> , 2019, 29, 1901-1910.	2.1	11
40	Conversion surgery for positive peritoneal washing cytology in pancreatic cancer. <i>BMJ Case Reports</i> , 2019, 12, e229993.	0.5	4
41	A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. <i>Journal of Gastroenterology</i> , 2019, 54, 194-203.	5.1	61
42	Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/J SAP05). <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 190-194.	1.3	329
43	Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19â€“9 is Highâ€“Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively Resected Pancreatic Adenocarcinoma. <i>World Journal of Surgery</i> , 2019, 43, 634-641.	1.6	25
44	The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (randomized phase II/III trial; Prep-02/J SAP-05).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4126-4126.	1.6	38
45	Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/J SAP-05).. <i>Journal of Clinical Oncology</i> , 2019, 37, 189-189.	1.6	185
46	Progesterone arrested cell cycle progression through progesterone receptor isoform A in pancreatic neuroendocrine neoplasm. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2018, 178, 243-253.	2.5	4
47	Increased Bile Acid Signals After Duodenal-Jejunal Bypass Improve Non-alcoholic Steatohepatitis (NASH) in a Rodent Model of Diet-Induced NASH. <i>Obesity Surgery</i> , 2018, 28, 1643-1652.	2.1	16
48	A novel liver metastasis-correlated protein of pancreatic neuroendocrine neoplasm (PanNEN) discovered by proteomic analysis. <i>Oncotarget</i> , 2018, 9, 24291-24303.	1.8	9
49	Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis. <i>Annals of Surgery</i> , 2017, 265, 397-401.	4.2	86
50	Locally advanced pancreatic cancer successfully treated by distal pancreatectomy with celiac axis resection (DP-CAR) after S-1 with radiation therapy followed by gemcitabine/nab-paclitaxel therapy: a case report. <i>Surgical Case Reports</i> , 2017, 3, 15.	0.6	6
51	Predictive risk factors for peritoneal recurrence after pancreatic cancer resection and strategies for its prevention. <i>Surgery Today</i> , 2017, 47, 1434-1442.	1.5	20
52	Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors. <i>Investigational New Drugs</i> , 2017, 35, 499-508.	2.6	27
53	Retrospective Study of the Correlation Between Pathological Tumor Size and Survival After Curative Resection of T3â€“Pancreatic Adenocarcinoma: Proposal for Reclassification of the Tumor Extending Beyond the Pancreas Based on Tumor Size. <i>World Journal of Surgery</i> , 2017, 41, 2867-2875.	1.6	5
54	A case of adult undifferentiated embryonal sarcoma of the liver successfully treated with right trisectionectomy: a case report. <i>Surgical Case Reports</i> , 2017, 3, 19.	0.6	21

#	ARTICLE	IF	CITATIONS
55	A long-term survival case treated with conversion surgery following chemotherapy after diagnostic metastasectomy for pancreatic cancer with synchronous liver metastasis. <i>Surgical Case Reports</i> , 2017, 3, 132.	0.6	6
56	A case of mucinous cystic neoplasm of the pancreas with spontaneous rupture. <i>Suizo</i> , 2017, 32, 767-774.	0.1	2
57	A Giant Intraductal Papillary Mucinous Neoplasm of the Pancreas Which Was Resectable by Cystectomy. <i>Japanese Journal of Gastroenterological Surgery</i> , 2017, 50, 303-310.	0.1	0
58	Prognosis after surgical treatment for pancreatic cancer in patients aged 80 years or older: a multicenter study. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2016, 23, 188-197.	2.6	40
59	Biliopancreatic limb plays an important role in metabolic improvement after duodenal jejunum bypass in a rat model of diabetes. <i>Surgery</i> , 2016, 159, 1360-1371.	1.9	52
60	Lymph Nodes Surrounding the Inferior Mesenteric Vein. <i>Japanese Journal of Gastroenterological Surgery</i> , 2016, 49, 261-266.	0.1	1
61	Strategy of symptom-targeted intervention based on patient quality of life at three months after pancreatectomy. <i>Suizo</i> , 2015, 30, 654-662.	0.1	3
62	Reappraisal of Peritoneal Washing Cytology in 984 Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Margin-Negative Resection. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 6-14.	1.7	51
63	Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients. <i>Journal of Gastroenterology</i> , 2015, 50, 694-702.	5.1	63
64	Silencing of LRRFIP1 reverses the epithelial-mesenchymal transition via inhibition of the Wnt/ β -catenin signaling pathway. <i>Cancer Letters</i> , 2015, 365, 132-140.	7.2	38
65	Mass spectrometry-based proteomic analysis of formalin-fixed paraffin-embedded extrahepatic cholangiocarcinoma. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2015, 22, 683-691.	2.6	11
66	Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study. <i>Pancreatology</i> , 2015, 15, 674-680.	1.1	95
67	Impact of Preoperative Biliary Drainage on Long-Term Survival in Resected Pancreatic Ductal Adenocarcinoma: A Multicenter Observational Study. <i>Annals of Surgical Oncology</i> , 2015, 22, 1238-1246.	1.5	50
68	A GNAS Mutation Found in Pancreatic Intraductal Papillary Mucinous Neoplasms Induces Drastic Alterations of Gene Expression Profiles with Upregulation of Mucin Genes. <i>PLoS ONE</i> , 2014, 9, e87875.	2.5	55
69	Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: Project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2014, 21, 148-158.	2.6	45
70	Angiogenesis and vascular maturation in neuroendocrine tumors. <i>Human Pathology</i> , 2014, 45, 866-874.	2.0	30
71	Neoadjuvant Chemotherapy with Gemcitabine and S-1 for Resectable and Borderline Pancreatic Ductal Adenocarcinoma: Results from a Prospective Multi-institutional Phase 2 Trial. <i>Annals of Surgical Oncology</i> , 2013, 20, 3794-3801.	1.5	131
72	Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin-fixed paraffin-embedded tissues. <i>International Journal of Cancer</i> , 2013, 132, 1368-1382.	5.1	74

#	ARTICLE	IF	CITATIONS
73	DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2012, 421, 98-104.	2.1	88
74	GCF2/LRRFIP1 promotes colorectal cancer metastasis and liver invasion through integrin-dependent RhoA activation. <i>Cancer Letters</i> , 2012, 325, 99-107.	7.2	36
75	Middle pancreatectomy. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2012, 19, 148-151.	2.6	6
76	Identification of epigenetically silenced genes in human pancreatic cancer by a novel method â€œmicroarray coupled with methyl-CpG targeted transcriptional activationâ€ (MeTA-array). <i>Biochemical and Biophysical Research Communications</i> , 2011, 411, 162-167.	2.1	34
77	Retrospective Evaluation of the Influence of Postoperative Tumor Marker Status on Survival and Patterns of Recurrence After Surgery for Pancreatic Cancer Based on RECIST Guidelines. <i>Annals of Surgical Oncology</i> , 2011, 18, 371-379.	1.5	36
78	GCâ€binding factor 2 interacts with dishevelled and regulates Wnt signaling pathways in human carcinoma cell lines. <i>International Journal of Cancer</i> , 2011, 129, 1599-1610.	5.1	17
79	RNA Interference Targeting Aurora Kinase A Suppresses Tumor Growth and Enhances the Taxane Chemosensitivity in Human Pancreatic Cancer Cells. <i>Cancer Research</i> , 2005, 65, 2899-2905.	0.9	212